Pfizer, GSK commit supplying developing world with vaccines

Chrysalis lists among its partners early-stage biotechnology companies, contract research organizations, top-10 pharmaceutical firms, and various other life sciences stakeholders.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Most of the company’s new additions, if not already online, will be scheduled for commissioning, validation, or qualification before the fourth quarter of 2025.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

The company describes the compact system as ergonomically designed, providing precision dosing and production floor flexibility.

The new lab will be used to develop and scale innovations for the production of medicines and to help secure the supply chain.